Camp4 Therapeutics Corp. CAMP 深 滬
等待開盤 09-18 09:30:00 美东时间
2.59
-0.180
-6.50%
華盛通- 最 高2.7786
- 今 開2.72
- 成交量 11.61万股
- 最 低 2.59
- 昨 收 2.77
- 總市值 5221.72万
- 52周最高 12.30
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.40
- 委 比 65.54%
- 總股本 2016.11万
- 歷史最高 12.30
- 量 比 0.01
- 振 幅 6.81%
- 歷史最低 0.40
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JP Morgan Downgrades Camp4 Therapeutics to Neutral
JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.
09-16 18:41
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 239.0% to ...
09-10 20:11
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation announced it has secured up to $100 million in financing, with $50 million upfront and potential for an additional $50 million, to fund a Phase 1/2 clinical trial for SYNGAP1-related disorders, expected to begin by mid-2026. Doug Williams, Ph.D., was appointed Board Chair, and Dan Tardiff, Ph.D., became Chief Scientific Officer. The financing was led by Coastlands...
09-10 11:00
REGENXBIO Announces Data From Phase I/II/III CAMPSIITE Trial Of Clemidsogene Lanparvovec For Treatment Of Patients With Mucopolysaccharidosis Type II At ICIEM 2025
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II>80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain disease, sustained
09-05 19:08
Campus Activewear Announces AGM and Book Closure Dates
Campus Activewear Ltd. ( ($IN:CAMPUS) ) has issued an announcement. Campus Acti...
08-30 05:10
CAMP4 Therapeutics Reports Q2 2025 Progress and Outlook
CAMP4 Therapeutics Corporation ( ($CAMP) ) has released its Q2 earnings. Here i...
08-28 12:11
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients.
08-20 00:01
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics announced positive translational data from its SYNGAP1 program, showing efficacy in a humanized mouse model and increased protein in non-human primates. They plan to initiate GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025 and report data from Phase 1 trials for CMP-CPS-001 in Q4. Financially, the company had $39.1 million in cash as of June 2025, with increased R&D and G&A expenses. They remain committed to advancing their...
08-14 20:05
